<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05389930</url>
  </required_header>
  <id_info>
    <org_study_id>2022003195</org_study_id>
    <secondary_id>R01AA029711</secondary_id>
    <nct_id>NCT05389930</nct_id>
  </id_info>
  <brief_title>Cannabis' Impact on Alcohol Consumption</brief_title>
  <official_title>Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study employs a repeated measures experimental design to examine the effect of&#xD;
      THC-dominant dose of cannabis and CBD-dominant dose of cannabis, relative to placebo, on&#xD;
      subsequent drinking in an alcohol choice task in which participants choose either to drink or&#xD;
      receive monetary reinforcement for drinks not consumed. Cannabis will be administered&#xD;
      simultaneously with an alcohol-priming dose or alcohol placebo.&#xD;
&#xD;
      The study will enroll up to 350 nontreatment-seeking heavy episodic alcohol drinkers who use&#xD;
      cannabis weekly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study employs a repeated measures experimental design to examine the effect of&#xD;
      THC-dominant (9.53% THC and 0.09% CBD) dose of cannabis and CBD-dominant (0.35% THC and&#xD;
      11.27% CBD) dose of cannabis, relative to placebo, on subsequent drinking in an alcohol&#xD;
      choice task in which participants choose either to drink or receive monetary reinforcement&#xD;
      for drinks not consumed. Cannabis will be administered simultaneously with an alcohol-priming&#xD;
      dose or alcohol placebo. The study will enroll up to 350 nontreatment-seeking heavy episodic&#xD;
      alcohol drinkers who use cannabis weekly to obtain the final sample of 200 with complete&#xD;
      data. Participants will be tested at a baseline session, during three experimental sessions,&#xD;
      and then during a subsequent 4-week period in the natural environment using a smart-phone&#xD;
      application. Findings have important implications for cannabis regulatory science and alcohol&#xD;
      use disorder treatment by addressing the relative impact of specific cannabinoids as well as&#xD;
      contextual risk in cannabis-alcohol co-use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2023</start_date>
  <completion_date type="Anticipated">March 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Mixed factorial design will use a 3 (within-subjects; cannabinoid dose: 9.53% THC/0.06% CBD, 11.27% CBD/0.35% THC, placebo) X 2 (between-subjects; cannabis + an alcohol-priming dose (0.3 g/kg) versus cannabis + alcohol placebo)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants are masked. Outcome assessors who have contact with participants are masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ml of alcohol consumed</measure>
    <time_frame>post-smoking during two-hours of the alcohol choice task</time_frame>
    <description>ml of alcohol consumed during the alcohol choice task</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Alcohol Drinking</condition>
  <condition>Cannabis Use</condition>
  <condition>Cannabis</condition>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>THC-dominant cannabis dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>367 mg of cannabis plant material with 9.53% THC and 0.09% CBD and 217 mg of placebo cannabis plant material will be mixed and smoked in a handheld pipe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD-dominant cannabis dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>367 mg of cannabis plant material with 11.27% CBD and 0.35% THC and 217 mg of placebo cannabis plant material will be mixed and smoked in a handheld pipe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>584 mg of cannabis plant material will be smoked in a handheld pipe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol priming dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alcohol: 0.3 g/kg. Alcohol priming drink is designed to raise blood alcohol levels to 0.03 g/dl and be consumed in 5 minutes. The drink is mixed using 80-proof liquor and juice. Participants are randomized to receive either the experimental alcohol priming dose or alcohol placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol placebo dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo beverage contains only juice and a negligible trace of alcohol for masking. The weight and sex-adjusted volume of alcohol and non-alcohol containing beverages will be equal. Participants are randomized to receive either the experimental alcohol priming dose or alcohol placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC-dominant cannabis</intervention_name>
    <description>Smoked cannabis with 9.53% THC and 0.09% CBD</description>
    <arm_group_label>Alcohol placebo dose</arm_group_label>
    <arm_group_label>Alcohol priming dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD-dominant cannabis</intervention_name>
    <description>Smoked cannabis with 0.35% THC and 11.27% CBD</description>
    <arm_group_label>Alcohol placebo dose</arm_group_label>
    <arm_group_label>Alcohol priming dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis placebo</intervention_name>
    <description>Smoked placebo cannabis plant material</description>
    <arm_group_label>Alcohol placebo dose</arm_group_label>
    <arm_group_label>Alcohol priming dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol</intervention_name>
    <description>Drink containing 0.3 g/kg of alcohol</description>
    <arm_group_label>CBD-dominant cannabis dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>THC-dominant cannabis dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol placebo</intervention_name>
    <description>Placebo beverage contains only juice and a negligible trace of alcohol for masking</description>
    <arm_group_label>CBD-dominant cannabis dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>THC-dominant cannabis dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 to 50&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  cannabis smoking in past two months&#xD;
&#xD;
          -  heavy drinking in past two months&#xD;
&#xD;
          -  in good physical health and weighing &lt; 250 lbs&#xD;
&#xD;
          -  zero breath alcohol at each visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  positive pregnancy test&#xD;
&#xD;
          -  nursing&#xD;
&#xD;
          -  positive urine toxicology screen for drugs other than cannabis&#xD;
&#xD;
          -  interest to quit or receive treatment for cannabis or alcohol use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Metrik, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Metrik, PhD</last_name>
    <phone>401-863-6650</phone>
    <email>Jane_Metrik@brown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Metrik, PhD</last_name>
      <phone>401-863-6650</phone>
      <email>Jane_Metrik@brown.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>May 20, 2022</study_first_submitted>
  <study_first_submitted_qc>May 20, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2022</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alcohol</keyword>
  <keyword>cannabis</keyword>
  <keyword>marijuana</keyword>
  <keyword>addiction</keyword>
  <keyword>cannabinoid</keyword>
  <keyword>tetrahydrocannabinol</keyword>
  <keyword>cannabidiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

